On August 31, SKB BIO fell 3.4% in regular trading, trading at 503.5 HKD/share, with turnover of approximately 13.62 million HKD. The decline came amid broad-based weakness across the biotechnology sector.

Within the Biotechnology sector where SKB BIO belongs, individual stocks were uniformly lower. Among peers, CANSINOBIO fell 6.05%, BEONE MEDICINES fell 3.30%, 3SBIO fell 2.77%, AKESO fell 2.57%, and INNOVENT BIO fell 2.33%. Sector-wide selling pressure appeared to be the primary drag on the stock.

Notably, southbound capital has been a net seller of SKB BIO shares for 17 of the past 20 trading sessions, with a cumulative net reduction of approximately 2.37 million shares over that period. The persistent institutional outflows add additional headwinds to the stock despite a strong fundamental backdrop, as the company reported its first-ever half-year profit of RMB 388 million on August 17, with product sales surging 112% year-over-year to RMB 657 million.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)